

Global Vaccine Safety Blueprint 2.0

(GVSB2.0)



2021–2023



World Health
Organization

Global Vaccine Safety Blueprint 2.0

(GVSB2.0)

2021–2023



**World Health
Organization**

Global vaccine safety blueprint 2.0 (GVSB2.0) 2021-2023

ISBN 978-92-4-003696-3 (electronic version)

ISBN 978-92-4-003697-0 (print version)

© World Health Organization 2021

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

Suggested citation. Global vaccine safety blueprint 2.0 (GVSB2.0) 2021-2023. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <https://www.who.int/about/policies/publishing/copyright>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.



Contents

Acknowledgments	v
Abbreviations and acronyms	vi
Prologue	vii
Introduction: Moving from a minimal and enhanced capacity concept to maturity levels	1
Strategic area I — Governance and systems development	6
Introduction	6
Governance	6
Rationale	6
Objective: provide the structure for effective decision-making in support of vaccine safety	7
System funding and financing	7
Rationale	7
Objectives	8
Objective 1: Encourage provision of adequate resources for the operations undertaken by public vaccine safety systems	8
Objective 2: Describe public vaccine safety funding options appropriate for the maturity level of the regulatory system in a country	9
Objective 3: Address injuries caused by vaccine reactions or vaccination errors	10
Strategic area II — Coordination of safety systems	11
Introduction	11
Rationale	11
Objectives	11
Objective 1: Coordination for exchange of information between vaccine manufacturers (or marketing authorization holders) and national regulatory authorities at local, regional and global levels	11
Objective 2: Coordination and information exchange between health authorities and other stakeholders at each level	12
Objective 3: Coordination and exchange of information between health authorities and advisory bodies at local, regional and global levels	13
Objective 4: Collaboration between the scientific community and health authorities	13
Objective 5: Communication between health authorities and the populations they serve	14
Strategic area III — Regulatory framework	15
Introduction	15
Rationale	15
Objectives	16
Objective 1: All countries should have provisions to establish vaccine pharmacovigilance, including laws, regulations, infrastructure, and lines of accountability	16
Objective 2: Ensure vaccine pharmacovigilance is a national, regional, and international responsibility	17
Objective 3: Develop human resources to perform regulatory safety surveillance activities	17

Strategic area IV — Surveillance of adverse events following immunization (AEFI)	19
Introduction	19
Rationale	19
Objectives	20
Objective 1: Detect and assess vaccine safety signals that warrant further investigation	20
Objective 2: Investigation of AEFIs	21
Objective 3: Conduct individual and population level AEFI causality assessment	22
Objective 4: Prevent vaccination adverse reactions	22
Objective 5: Strengthened capacity to address vaccine-related adverse events and communication response	23
Strategic area V — Enhanced vaccine safety communication	24
Introduction	24
Rationale	24
Objectives	25
Objective 1: Strengthen the capacity and infrastructure to communicate vaccine safety information and manage the communication response to vaccine safety related events	25
Objective 2: Identify and characterize vaccine safety concerns among the public, healthcare workers and other stakeholders as potential safety signals that warrant further investigation and a communication response	26
Objective 3: In a crisis, provide timely, short and clear messages to all stakeholders describing what is known, what is not known, and what is being done to fill these gaps	27
Strategic area VI — Fragile states and emergencies	28
Introduction	28
Rationale	28
Objectives	29
Objective 1: Use vaccine safety monitoring as a quality assurance mechanism for vaccination activities in fragile states and in emergency situations	29
Objective 2: Monitor the safety of novel vaccines for emerging infectious diseases during emergencies	30
Accountability framework	31
Rationale	31
Annex 1: GVSBI.0: minimal and enhanced capacity	33
Annex 2: Current WHO Benchmarking Tool sub-indicators of maturity levels	34
Annex 3: Objectives and strategies for each strategic area	37
References	43



Acknowledgments

This document was prepared to address the findings from background research published in July 2019 (1), under the leadership of the **WHO Secretariat for the Global Vaccine Safety Initiative** (Patrick Zuber, Christine Guillard, Isabelle Sahinovic, Madhava Ram Balakrishnan), based on a first draft prepared by the **Institute for Vaccine Safety (IVS) at Johns Hopkins Bloomberg School of Public Health** (Daniel A. Salmon, Matthew Z. Dudley, Tina Proveaux). The original draft was revised, based on comments received from two rounds of public consultation in October and November 2019, and from the Global Summit for Vaccine Safety in December 2019.

A Drafting Group provided advice throughout the process: Chair Edwin Asturias (University of Colorado), Adiel Saldaña (Instituto de Salud Pública de Chile), Jane Gidudu (US CDC), Priscilla Nyambayo (Medicines Control Authority of Zimbabwe), Lee Hampton (GAVI), Satinder Aneja (Lady Harding Medical College, Delhi India), Dure Samin Akram (Karachi, Pakistan), Gopa Raychaudhuri (US FDA), Ben Hickler (UNICEF), Robb Butler (UNICEF).

Subgroups were responsible for the development of the following sections:

Coordination of safety systems

Adiel Saldaña (Instituto de Salud Pública de Chile) (chair), José Luis Castro (PAHO), Marc Ceuppens (J&J), Katharina Hartmann (DCVMN), Corinne Jouquelet-Royer (Sanofi), Olga Menang (PATH), Jens-Ulrich Stegmann (GSK), Sonia Pagliusi (DCVMN), Christine Guillard (WHO HQ).

Governance and system development

Edwin Asturias (University of Colorado) (chair), Lee Hampton (GAVI), Sujeet Kumar Jain (WHO AFRO), Patrick Zuber (WHO HQ)

Regulatory framework

Gopa Raychaudhuri (US FDA) (chair), José Luis Castro (PAHO), Priscilla Nyambayo (Medicines Control Authority of Zimbabwe), Adiel Saldaña (Instituto de Salud Pública de Chile), Christine Guillard (WHO HQ).

AEFI surveillance and methodological enhancements

Dure Samin Akram (Karachi, Pakistan) (co-chair), Jane Gidudu (US CDC) (co-chair), Satinder Aneja (Lady Harding Medical College, Delhi India), Priscilla Nyambayo (Medicines Control Authority of Zimbabwe), Edwin Asturias (University of Colorado), Julianne Gee (US CDC), Narendra Arora (INCLEN, India), Houda Langar (WHO EMRO), Madhava Ram Balakrishnan (WHO HQ).

Enhanced vaccine safety communication (including social networks)

Robb Butler (UNICEF) (initial chair), Elisabeth Wilhelm (US CDC) (chair since mid-October 2019), Ben Hickler (UNICEF), Lisa Menning (WHO HQ), Isabelle Sahinovic (WHO HQ).

Fragile states and crisis situations

Ananda Amarasinghe (WHO WPRO) (chair), Edinam Agbenu (WHO AFRO), Alejandro Costa (WHO HQ), Dure Samin Akram (Karachi, Pakistan), Sujeet Kumar Jain (WHO AFRO), Patrick Zuber (WHO HQ).

Accountability framework

Jim Buttery (Monash University, Australia) (chair), Lee Hampton (GAVI), Christoph Steffen (WHO HQ) and Patrick Zuber (WHO HQ).

Abbreviations and acronyms

AEFI	Adverse events following immunization
AVSS	Active vaccine safety surveillance
CFS	Chronic fatigue syndrome
CIOMS	Council for International Organizations of Medical Sciences
CRPS	Complex regional pain syndrome
DHIS2	District Health Information System 2
GACVS	Global Advisory Committee on Vaccine Safety
GBT	Global Benchmarking Tool
GVSBI.0	Global Vaccine Safety Blueprint, 2012
GVSBI.0	Global Vaccine Safety Blueprint, 2021
GVSI	Global Vaccine Safety Initiative
ISRR	Immunization stress-related response
LLDB	Large linked data bases
LMIC	Low- and middle-income countries
MERS	Middle-East respiratory syndrome
NGO	Non-governmental organizations
NIOH	Norwegian Institute of Public Health
NITAG	National Immunization Technical Advisory Group
NRA	National regulatory authorities
POTS	Postural orthostatic tachycardia syndrome
RITAG	Regional Immunization Technical Advisory Group
SAGE	Strategic Advisory Group of Experts
SARS	Severe acute respiratory syndrome
SF	Substandard and falsified health products

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_23347

